

MeetEU Project - Team Heidelberg - Team 1 –
Identification and Enhancement of novel Sars-CoV-2 NSP13 Helicase
Inhibitors

Linda Blaier, Paul Brunner, Selina Ernst, Valerie Segatz, and Chloé Weiler

February 2024

1 Abstract

Although the development of vaccines against Sars-CoV-2 was successful during the recent pandemic, the amount of FDA approved drugs for the therapy of Covid-19 is still limited to Paxlovid and Veklury, Olumiant and Actemra (FDA 2023). One possibility to accelerate the development of new therapies for Covid19 is to screen already approved drugs for effects against the viral reproduction. In this years MeetEU project, we investigated the NSP13 helicase of Sars-CoV-2 and tried to find compounds that could be repurposed for this therapy, as well as novel compounds that could lead to an effective treatment of Covid19. Using our *in-silico* pipeline (see graphical abstract) enables us to evaluate possible drug candidates, suggest novel structures based on already approved drugs and investigate their toxicity, while being cheaper and less labor intensive than projects limited to wet-lab work.

Abbreviations

ADP	adenosine diphosphate
ATP	adenosine triphosphate
COVID-19	coronavirus disease 2019
FDA	food and drug administration
MD	molecular dynamics
MM-PBSA	molecular mechanics energies combined with the Poisson-Boltzmann and surface area continuum solvation
NSP13	non-structural protein 13
RAS	renin-angiotensin system
RCSB PDB	Research Collaboratory for Structural Bioinformatics Protein Data Bank
RMSD	root mean square deviation
RMSF	root mean square fluctuation
RTC	replication transcription complex
SARS-CoV-2	severe acute respiratory syndrome coronavirus type 2
SAscore	synthetic accessibility score
ssRNA	single-stranded RNA
ZBD	zinc-binding domain

2 Introduction

In the wake of the successful development of vaccines against **SARS-CoV-2!** (**SARS-CoV-2!**) during the recent pandemic, the amount of FDA-approved drugs for the therapy of **COVID-19!** (**COVID-19!**) remain limited to Paxlovid, Veklury, Olumiant, and Actemra (FDA 2023). Expanding the repertoire of drugs available for treating **COVID-19!** is particularly crucial for high-risk individuals, as vaccines may not fully prevent infections. The goal of this year’s Meet-EU project is to develop a pipeline for identifying potential inhibitors targeting the SARS-CoV-2 helicase also known as **NSP13!** (**NSP13!**). This protein is considered a promising drug target for two reasons. Firstly, **NSP13!** is part of the **RTC!** (**RTC!**) which is essential for viral RNA synthesis (Malone et al. 2022). Secondly, its high conservation across coronaviruses means that there is a reduced likelihood of the virus developing resistances to drugs targeting **NSP13!** through mutations of the viral genome (Spratt et al. 2021). Consequently, effective **NSP13!** inhibition would significantly impede viral replication and therefore its spread within the host. **NSP13!** consists of five domains, namely the **ZBD!** (**ZBD!**) with the accessory 2B domain, the α -helical stalk domain, as well as the RecA-like 1A and 2A domains (Marecki et al. 2021). The gap between the RecA-like domains and the 2B domain encompass the site for ATP and RNA binding (Newman et al. 2021). In the **RTC!** the NSP13 helicase is present as a homodimer. Nevertheless, only one of the copies complexes with a single-stranded RNA **ssRNA!** (**ssRNA!**). Therefore, it was proposed in previous publications that the catalytically active form of the **NSP13!** helicase is the monomer (Berta et al. 2021).

Computer-aided, structure-based drug discovery is employed for identification of known drugs for their potential as inhibitors of the **NSP13!** helicase which can then be further investigated in experimental laboratory settings. This process involves several steps: (i) Identification of potential drug binding sites, (ii) high-throughput screening of ligands to assess their binding efficacy within the designated pocket, followed by (iii) the evaluation of the binding pathways, kinetics, and thermodynamics (Śledź and Caffisch 2018). Focussing this screening on well-documented or already FDA-approved compounds is very attractive, as drug repurposing has the potential to shorten the development period and therefore also the development costs (Pushpakom et al. 2019).

2.1 Identification of Consensus Binding Pocket

In drug discovery, the initial step is to investigate the protein structure in order to analyse potential binding sites. These are cavities on the surface or interior of the protein with suitable properties to bind a ligand. The functionality of a binding pocket is determined by its shape and location, but also by the amino acid residues which define its physicochemical characteristics (Stank et al. 2016). Different experimental and theoretical procedures exist to analyse the druggability of such binding pockets. In this work, we combined three different *in silico* tools, each following a different algorithm. *Fpocket* (Le Guilloux et al. 2009) utilises a geometry-based algorithm based on Voronoi tessellation and sequential clustering to determine potential binding sites. We also used PRankweb which is the web interface based on the P2Rank standalone method which is based on a machine-learning algorithm (Krivák and Hoksza 2018; Jendele et al. 2019; Jakubec et al. 2022). P2Rank assigns structural, physicochemical, and evolutionary features to points on the solvent-accessible surface of a protein. From this information, the machine-learning model is built and used to predict and rank potential ligand binding sites. Lastly, FTMAP (Brenke et al. 2009) was used to validate the binding pocket found with the previously mentioned approaches. FTMAP uses docking results of sixteen small molecules differing in polarity, shape, and size to identify binding hot spots with a fast Fourier transform correlation. The most favourable docked confirmations are determined through energy minimisation and clustering processes. Finally, the results of all three tools were combined to

identify a consensus binding pocket of the NSP13 helicase. The resulting coordinates of the consensus binding pocket were then used for molecular docking simulations.

2.2 Molecular Docking

Molecular Docking programs are used to evaluate binding affinities between a potential drug candidate and the target protein. A key aspect of this task is the prediction of the ligand position, orientation, and conformation. Search-based methods approach this task by continuously modifying the ligand pose, while estimating its quality or likelihood (score) and stochastically trying to infer the global optimum of the scoring function. Among the most widely used tools are *AutoDock Vina* (Trott and Olson 2010) and *Glide* (Halgren et al. 2004), which mainly differ in their scoring functions. However, such search-based methods are computationally expensive. Therefore, in order to be able to screen large datasets, search-based methods are generally restricted to a previously defined binding pocket (Corso et al. 2022). Consequently, potential other binding sites of a ligand are not assessed. Machine learning-based blind docking approaches try to address that problem by stochastically predicting binding pocket and ligand pose based on learned characteristics and aligning them. The most promising results are achieved by using *Diffdock* (Corso et al. 2022), a generative model which applies a reverse diffusion process to the docking paradigm. In this manner, *Diffdock* iteratively transforms an uninformed noisy distribution over ligand poses defined by the degrees of freedom involved in docking (position, turns around its centre of mass, and twists of torsion angles) into a learned model distribution (Corso et al. 2022). Corso et al. thereby describe this process as a progressive refinement of random ligand poses via updates of their translations, rotations and torsion angles.

2.3 Estimation of Toxicity and Synthetic Accessibility

After identifying the lead compounds that exhibit optimal binding affinity within the consensus pocket, an evaluation of the general toxicity and synthetic accessibility of these compounds was performed using the latest version of *eToxPred* (Pu et al. 2019). This additional step helps estimate the suitability of the compounds as real-life pharmaceuticals against COVID-19. The Tox-score allows for a general assessment of the predicted risk vs. benefit ratio of the potential NSP13 inhibitors. Moreover, *eToxPred* allows for an insight into the ease of synthesis, indicated by the synthetic accessibility score **SAscore!** (**SAscore!**). This score reflects the ease and efficiency of producing the molecules in large quantities and consequently their feasibility as potential drugs.

2.4 Molecular Dynamics Simulation

As the last step of our pipeline, an **MD!** (**MD!**) simulation is conducted using the best-scoring compounds as a ligand in the binding pocket of the **NSP13!** protein. Simulating the movement of molecules in a system based on the attractive and repulsive forces between atoms helps with understanding the molecular interplay between the found ligands and the binding pocket. Whether the ligand stays inside the binding pocket throughout the whole simulation gives an estimate of how strongly it binds to the protein (Durrant and McCammon 2011). As this is the final step of our pipeline, the result of this simulation estimates how the ligand would perform if administered *in-vitro*. Additionally, the frames generated by the software can be used to calculate different metrics regarding the binding strength, like the **RMSF!** (**RMSF!**), **RMSD!** (**RMSD!**) and the binding affinities estimated by **MM-PBSA!** (**MM-PBSA!**). The **RMSD!** measures the average displacement of the atoms throughout the simulation compared to the first frame of the simulation and estimates how much the protein moves and changes conformations over time. The **RMSF!** on the other hand calculates the movement of a certain atom or group of atoms over time compared to the

average position of the atoms and groups (Martinez 2015). **MM-PBSA!** is able to estimate the binding affinity of the simulated protein-ligand pair (Genheden and Ryde 2015).

3 Material and Methods

3.1 Datasets from ZINC20 and ECBD

A total of 1616 **FDA!** (**FDA!**)-approved drugs were downloaded in *.sdf* format from the ZINC database (Irwin et al. 2020). Additionally, 5016 files were retrieved, downloading the pilot library from the ECBD database.

3.2 Receptor and Ligand Preparation

In this project we analysed crystal structures of the **SARS-CoV-2! NSP13!** helicase which were obtained by (Newman et al. 2021) in a crystallographic fragment screening. Thus, the three protein structures (PDB codes: 6ZSL, 5RME, 5RM2) were downloaded from the protein data bank **RCSB PDB!** (**RCSB PDB!**). All three structures were used to determine a consensus binding pocket. As 6ZSL is the crystal structure with the highest resolution of 1.94 Å and the other two structures show the **NSP13!** helicase complexed with a different fragment, we selected 6ZSL for further analysis in our drug discovery pipeline. Although the helicase is a homodimer, it was found that only the monomer is the catalytically active form (Berta et al. 2021). Therefore, we concentrated our drug discovery only on the monomer of the helicase, namely on chain A.

Protein Data Bank (PDB) files often contain problems that first need to be resolved so they can be used for further simulations. Therefore, we prepared the PDB protein structure using the *PDBFixer* (Version 1.9) application, which among other things adds missing hydrogen and heavy atoms, builds missing loops and replaces non-canonical with canonical amino acids (Eastman et al. 2017). Here, we added hydrogen atoms appropriate for the physiological pH of 7.4. The B chain of 6ZSL, identical to the A chain, contained in the crystallographic structure was removed as well as all phosphates and the ligands contained in the protein structures of 5RME and 5RM2. Additionally, for molecular docking using *AutoDock Vina* and for the **MD!** simulation the zinc ions were removed. For consensus binding site detection 6ZSL was used as a reference structure to align 5RME and 5RM2 in *PyMol* (Version 2.5.7, Schrödinger, LLC (2023)). This allowed better visualization and superimposition of the results.

Ligands were prepared using *OpenBabel* (Version 3.1.1, O’Boyle et al. (2011)) in order to convert implicit hydrogens into explicit hydrogens, to generate the necessary 3D structures of the ligands, and to split multi-molecule files into single ones. *ADFR suite* (Version 1.0, Ravindranath et al. (2015)) was further used in order to convert all files into the *.pdbqt* format, which is required by *Autodock Vina* (Trott and Olson 2010).

3.3 Consensus binding site detection

To identify a potential ligand binding site of the NSP13 helicase, three different tools based on different methods were used on Chain A of the crystal structures 6ZSL, 5RM2, and 5RME: (i) *Fpocket* (Version 3.0, Le Guilloux et al. (2009)), (ii) *PrankWeb 3* (accessed on... , Krivák and Hoksza (2018), Jendele et al. (2019), and Jakubec et al. (2022)), and (iii) *FTMap* (accessed on..., Brenke et al. (2009)). For *Fpocket*, only pockets with a **DScore!** (**DScore!**) above 0.2 were considered. These were loaded into *PyMol* (Version 2.5.7, Schrödinger, LLC (2023)) together with the pockets detected with the other tools. Next, we focused only on the calculated pockets calculated by *Fpocket* and *PrankWeb* and identified overlapping pockets using the amino acid sequence and the visualization

of the different pockets. These were then considered as one consensus binding site. Since, *FTMAP* follows a docking approach of sixteen small probes rather than calculating pockets, this tool was used to validate that indeed clusters of the small molecules formed inside of the potential consensus binding pocket. Lastly, the coordinates of the consensus binding pocket needed for molecular docking were calculated using the public server at *usegalaxy.org* of the Galaxy web platform (Afgan et al. 2016). The docking box size was set to 30\AA^3 .

3.4 Molecular Docking

The molecular docking was performed twice. For that first step *AutoDock Vina* (Version 1.1.2, henceforth abbreviated as *Vina*, Trott and Olson (2010)) was utilised. Especially for *Vina* the zinc ions were removed and the resulting structure was converted into the *.pdbqt* format through *AutoDockTools* (Version 1.5.7 (Goodsell et al. 2021)). The consensus pocket was introduced as the grid box with lengths of 30\AA . The exhaustiveness was set to 30 and the maximum number of binding modes to 9. Taking advantage of multithreading, **Vina!** (**Vina!**) used the 28 CPUs accessible on the multi-core server (Che et al. 2023). A filter was applied on the set of ligands assuring only 3D structures smaller than the specified grid box were screened against the receptor (1428 from the ZINC database and 3592 from the ECBD database). The filter was implemented in Python (Version 3.11.6, Van Rossum and Drake (2009)) and executed together with the *Vina* command in Bash script. The resulting nine different conformations for each ligand were ranked by their affinity scores and only the best value was considered in further steps. A number of ligands were later found to have multiple docking results due to an overlap between the two datasets and in accordance with previous steps only the best score was kept. The remaining 4863 ligands were ranked by their affinity score and the top one hundred were selected for next steps.

A second molecular docking was performed with those top scorers from the screening as well as **ADP!** (**ADP!**) and **ATP!** (**ATP!**). The docking software *Glide* provided by *Schrödinger Inc.* (Friesner et al. 2004) was accessed through *Maestro* (Version 2022.3, Schrödinger Release 2022-3). The included tools *Protein Preparation Wizard* and *LigPrep* (Madhavi Sastry et al. 2013) were utilized to prepare the monomer helicase and ligands for the docking process with the OPLS4 force field (Lu et al. 2021). For this docking process the zinc ions from the original structure were retained. The pH value was set to 7.0. Depending on the initial structure the ligand preparation generates a varying amount of conformations. In the analysis of the results only the best-performing conformation was included. The *Receptor Grid Generation tool* was used to generate the receptor grid with the same binding pocket as in *Vina*. The docking with *Glide* was performed at standard precision mode and with flexibility of the ligands enabled (Halgren et al. 2004). The criteria for the selection of the best-performing ligands was chosen to be the docking score. The interactions between the top scoring ligands and the receptor were documented.

3.5 Estimation of Toxicity and Synthetic Accessibility

The general toxicity and synthetic accessibility of the given compounds was estimated using the machine-learning tool *eToxPred* (Pu et al. 2019). The SMILES files of the Top100 compounds from *AutoDock Vina* (Trott and Olson 2010) served as input for the pre-trained model. The toxicity predictor was pre-trained on the FDA-approved and the KEGG-drug datasets whose compounds were considered non-toxic as well as the TOXNET and the T3DB datasets whose compounds were considered toxic using a deep-belief-network based model. This predictor yields a Tox-score between 0 and 1 and in accordance to the paper, all compounds with a Tox-score below 0.58 were deemed non-toxic. The synthetic accessibility was reflected in a **SAscore!** which was obtained by training an extra-trees-based classifier on NuBBE, UNPD, FDA-approved, and DUD-E-active datasets.

3.6 Validation of the binding-site for the Top100 scorer

The likelihood of our Top100 scorer binding within our consensus pocket was validated by blind docking via *Diffdock* (Corso et al. 2022). Thereby, all required sdf files were transformed into SMILES using *OpenBabel* (Version 3.1.1, O’Boyle et al. (2011)). As receptor, the prepared 6ZSL PDB files were utilised. *Diffdock* was performed using the pretrained scoring model¹ to infer ligand conformations and ranking based on the included confidence model². The proposed default settings were used for the inference. These contained 20 inference steps, the generation of 40 samples per ligand, a batch-size of 10 and 18 actual denoising steps, whereby no noise was used for the final step of the reverse diffusion process. For the analysis of the *Diffdock* output, the maximum and minimum coordinates for all samples generated per ligand were extracted using *PyMOL* (Version 2.5.5, Schrödinger, LLC (2015)) and aligned with the coordinates of our consensus pocket in Python (Version 3.10, Van Rossum and Drake (2009)). Based on that, the mean number of ligands within our binding site was calculated and set into relation to the rank posed on the ligand samples by the *Diffdock* confidence score.

3.7 Molecular Dynamics Simulation

In order to validate the binding of the discovered compounds, we used *GROMACS* (Version 2023.3, Abraham et al. (2015)) to simulate the drugs inside of the consensus binding site of NSP13. To do so, the Protein-Ligand Complex tutorial by Lemkul was followed (Lemkul 2018). The a99SB-disp forcefield was used, as it was shown to recreate protein structures in different environments very accurately (Robustelli et al. 2018). The 6ZSL A-chain PDB file was first turned into the fitting *GROMACS* format (*.gro*) the general simulation parameters were set up. As the ligands feature bonds and atoms not commonly seen in proteins, it is necessary to create a fitting force-field for them. For this, *acpype* (Silva and Vranken 2012) was used. The output files from *Maestro Glide* were converted to PDB and then piped into of *acpype* which uses the given PDB file and information about the charges on the compound to create files that enable us to add the compound to the simulation environment. The output was then combined with the *GROMACS* topology and *.gro* files manually, according to Lemkul. Following the tutorial, the simulation space was set up, filled with water (a99SBdisp_water used as its force-field) and ions were added to create a net zero charge system. As it is common the charges were equalized using sodium and chloride ions. Energy-minimization was conducted and *NVT* and *NPT* equilibration was run. This ensures a somewhat stable starting point for the simulation. The production run was set to simulate 100 ns. The *.mdp* file containing the simulation parameters used for the final production run can be seen in the Github repository. Additionally, a second **MD!** simulation was run using ANP as the ligand. This is supposed to help compare the result of the first simulation, as ANP is very close to the true ligand of the pocket, ATP. For the analysis of the simulation, *GROMACS* internal tools were used to calculate the RMSD and RMSF of the protein. These scores give us insight into the movement and conformational changes during the simulation regarding protein and ligand. Furthermore, the simulation frames were extracted and rendered into a video using *VMD* (Humphrey et al. 1996). For MM-PBSA calculations we used *gmx_MMPBSA* (Miller et al. 2012). This package enables direct estimation of binding affinities using the *GROMACS* output files.

¹https://github.com/gcorso/DiffDock/tree/bc6b5151457ea5304ee69779d92de0fded599a2c/workdir/paper_score_model

²https://github.com/gcorso/DiffDock/tree/bc6b5151457ea5304ee69779d92de0fded599a2c/workdir/paper_confidence_model

4 Results

4.1 Top 100 Compounds Exhibit Low Toxicity and High Synthetic Accessibility

After identifying the top 100 best-binding ligands through AutoDock Vina, our subsequent analysis focused on evaluating their practical applicability as potential drugs by considering their predicted toxicity and synthetic accessibility. The resulting SAScore and Tox-Score for each compound were visualised in a scatter plot as seen in Figure ??.

Of those 100 compounds, 99 presented with a Tox-score below the threshold of toxicity, indicating a low probability of being toxic to humans. The overall median Tox-Score is 0.24, with a mean of 0.26 across all compounds. Across all compounds the median SAScore of 2.69 and a mean of 2.87 which suggests that they are generally easy to synthesise. The top scorer from Glide, ZINC000096077632, was predicted to have a Tox-Score of 0.14 and an SAScore of 5.02.

4.2 Molecular Dynamics Simulation Validates Binding of Top Scorer

The **MD!** simulation is integral to validate the results of our pipeline. After the production run was finished, the resulting trajectory file was centred on the protein and modified to remove any ghosting and splitting of the protein at the borders of the simulation box. The last frame of the simulation was extracted and visualized using *pyMOL* (Schrödinger, LLC 2015), which can be seen in Figure ?. The figure clearly demonstrated, that the top scoring compound of our Glide screening stayed inside of the binding pocket until the end of the simulation. This was also confirmed by manual inspection of the frames generated in the simulation, which were combined to a video file using *VMD*. Furthermore, the polar interactions between the ligand and residues in its proximity are shown. It seems, that EOS100380 is bound to the protein by interactions with Glu319, Lys320 and Arg442 of the NSP13 helicase. These interactions could also be validated using *LigPlot+* (Laskowski and Swindells 2011).

To investigate the dynamics of these interactions between ligand and protein, the **RMSD!** and **RMSF!** were calculated, which can be observed in Figure ?. The **RMSD!** observed over the course of the simulation (Figure ??A) rises at first, but reaches a plateau after roughly 60 ns. The RMSD seems to settle at roughly 0.5 nm, which is slightly larger than expected. Investigation into the RMSF per residue (Figure ??B) suggests, that some residues move significantly more than others. The highly mobile residues seem to be located in the zinc binding domain and domains 1B and 2A. The latter two play a role in the binding of the ligand. Thus movement in these parts of the protein was to be expected. All in all, the protein seems to undergo conformational changes, however it does not show major signs of instability. Further proof of this behaviour can be seen when investigating the radius of gyration (Supplementary Figure ?). The estimation of the binding energy by MMPBSA returned a $\Delta G_{solv} = -9.98 \frac{\text{kcal}}{\text{mol}}$. The RMSD and RMSF of the simulation using ANP as the ligand can be seen in Supplementary Figure ?. The system shows a generally lower RMSD and an earlier plateau compared to the first simulation. For the RMSF a similar trend can be observed, especially looking at the ZBD.

Workflow_MeetEU.pdf

Proposed workflow for the discovery of NSP13 helicase inhibitors.




Figure 1: **Scatter plot of predicted toxicity and synthetic accessibility of the 100 best-binding compounds.** The predicted **SAscore!** was plotted against the Tox-Score for the top 100 best scorers from AutoDock Vina. The top 3 scorers from Glide are highlighted in red. The vertical gray line represents the threshold for the toxicity, with the compounds to the right of this line being considered non-toxic.



Figure 2: **Visualisation of EOS100380 inside the binding pocket at the end of 100 ns simulation.** The polar interactions are marked with yellow dotted lines. The amino acids involved in these interactions are labelled.




Figure 3: **RMSD and RMSF of the protein backbone during the simulation.** The RMSD was plotted over time for the whole 100 ns simulation. The RMSF is shown per residue. The colour bar annotates the protein domain the respective residue belongs to, according to Jia et al. (2019). ZBD = Zinc Binding Domain

5 Discussion and Outlook

The Tox-Score predictor of *eToxPred* was trained using **FDA!**-approved dataset as non-toxic incidences. Consequently, the low mean Tox-Score of the tested compounds aligns with our expectation, considering that the compounds from the ZINC database are derived from an **FDA!**-approved dataset. The single toxic incidence we detected was from the ECBD database which was comprised of **FDA!**-approved and non-**FDA!**-approved molecules. As highlighted by Pu et al., natural compounds typically exhibit higher **SA**score! values compared to synthetic compounds due to their inherent complexity (Pu et al. 2019). The relatively high **SA**score! of ZINC000096077632 can be explained by the fact that ZINC000096077632 corresponds to angiotensin-(1-7) which is a naturally occurring compound with a crucial role in the **RAS!** (**RAS!**) ([santos2014angiotensin](#)). The analysis of natural compound datasets by Pu et al. revealed a bimodal distribution in the **SA**score!, with peaks around 3 and 5. Furthermore the very low Tox-Score of the top scorer can also be explained by the fact that it is a naturally occurring molecule in the human body.

The investigation into the **MD!** (**MD!**) simulation further validated the viability of our pipeline. The RMSD of the backbone protein atoms (see Figure ??A) was slightly higher than anticipated, as it seemed to generally be smaller in the tutorials provided by Lemkul. However, the system stabilised over the duration of the simulation. Looking at the RMSF per residue (see Figure ??B) it is apparent, that certain domains of the protein lead to this increase in the RMSD. Especially the zinc binding domain shows a lot of movement. When discussing the general movement of domains in such simulations one should keep in mind, that the NSP13 A-chain is part of a much bigger replication complex (Newman et al. 2021) in an *in-vitro* setting. The conformational changes seen in this analysis would be severely hindered by other components in the complex. The domains 1B and 2A were suspected to be involved in a lot of conformational changes, as they make up a large part of the interaction surface between the protein and the ligand. The RMSD is calculated versus the output of Glide as a reference structure. It is completely possible that the system created by Glide is not completely relaxed. Thus conformational changes are to be expected when protein and ligand can suddenly move freely. Comparing the simulation with our top scoring ligand to the one with ANP shows less movement in the ANP run. This was to be expected, as ANP is very close to the original ligand of the helicase (ATP). Furthermore, the crystal structure used as input for the second run already had the ANP bound to begin with. This leads to a more relaxed starting point in general. Comparing RMSD and RMSF however, shows similarities, especially regarding the mobility of the ZBD. This further strengthens our confidence in our pipeline. All in all, the analysis offers confidence, that EOS100380 binds to the NSP13 helicase and stays bound through an extended period of time.

6 Limitations of the project

Regarding the **MD!** (**MD!**) simulation, the project was held back by the tight time schedule of the Meet-EU seminar. Running simulations for other top scoring ligands would have helped immensely in validating out pipeline further and compare the results of the top scorer. Running multiple runs of the same simulation would have also further deepened our confidence in the results, as MD simulations in and of them selves are a very stochastic process and should always be estimated using replicas. Following the work of Raubenolt et al. (2022), implementing replica exchange with dynamical scaling would have elevated the validation step of this project. Access to more GPUs would have also made multiple simulations at once possible. Furthermore, the original plan to implement *AutoGrow4* (Spiegel and Durrant 2020) in order to improve our lead drugs and generate novel compounds was

hindered by technical problems, which could not be fixed with the limited time at our disposal. We believe, that the increase in diversity amongst the drug candidates would lead to a better final drug candidate. With the help of *eToxPred*, as shown in this report, the new compounds could have been evaluated for their toxicity and a well binding, not too cytotoxic lead could have been presented.

7 Supplementary Material



Figure S1: Radius of Gyration of the NSP13 protein through the production run featuring EOS100380.



Figure S2: RMSD and RMSF of Protein backbone for the simulation with ANP

References

- Abraham, M. J., T. Murtola, R. Schulz, S. Páll, J. C. Smith, B. Hess, and E. Lindahl (2015). “GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers”. In: *SoftwareX* 1, pp. 19–25. ISSN: 2352-7110. DOI: 10.1016/j.softx.2015.06.001.
- Afgan, E., D. Baker, M. Van den Beek, D. Blankenberg, D. Bouvier, M. Čech, J. Chilton, D. Clements, N. Coraor, C. Eberhard, et al. (2016). “The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2016 update”. In: *Nucleic acids research* 44.W1, W3–W10.
- Berta, D., M. Badaoui, S. A. Martino, P. J. Buigues, A. V. Pislakov, N. Elghobashi-Meinhardt, G. Wells, S. A. Harris, E. Frezza, and E. Rosta (2021). “Modelling the active SARS-CoV-2 helicase complex as a basis for structure-based inhibitor design”. In: *Chemical Science* 12.40, pp. 13492–13505.
- Brenke, R., D. Kozakov, G. Y. Chuang, D. Beglov, D. Hall, M. R. Landon, C. Mattos, and S. Vajda (2009). “Fragment-based identification of druggable ‘hot spots’ of proteins using Fourier domain correlation techniques”. In: *Bioinformatics* 25.5, pp. 621–7. ISSN: 1367-4803 (Print) 1367-4803. DOI: 10.1093/bioinformatics/btp036.
- Che, X., Q. Liu, and L. Zhang (2023). “An accurate and universal protein-small molecule batch docking solution using Autodock Vina”. In: *Results in Engineering* 19, p. 101335. ISSN: 2590-1230. DOI: <https://doi.org/10.1016/j.rineng.2023.101335>. URL: <https://www.sciencedirect.com/science/article/pii/S2590123023004620>.
- Corso, G., H. Stärk, B. Jing, R. Barzilay, and T. Jaakkola (2022). *DiffDock: Diffusion Steps, Twists, and Turns for Molecular Docking*. DOI: 10.48550/arXiv.2210.01776.
- Durrant, J. D. and J. A. McCammon (2011). “Molecular dynamics simulations and drug discovery”. In: *BMC Biology* 9.1, p. 71. DOI: 10.1186/1741-7007-9-71.
- Eastman, P., J. Swails, J. D. Chodera, R. T. McGibbon, Y. Zhao, K. A. Beauchamp, L.-P. Wang, A. C. Simmonett, M. P. Harrigan, C. D. Stern, R. P. Wiewiora, B. R. Brooks, and V. S. Pande (2017). “OpenMM 7: Rapid development of high performance algorithms for molecular dynamics”. In: *PLOS Computational Biology* 13.7, e1005659. DOI: 10.1371/journal.pcbi.1005659. URL: <https://doi.org/10.1371/journal.pcbi.1005659>.
- FDA (2023). *Know Your Treatment Options for COVID-19*. URL: <https://www.fda.gov/consumers/consumer-updates/know-your-treatment-options-covid-19>.
- Friesner, R. A., J. L. Banks, R. B. Murphy, T. A. Halgren, J. J. Klicic, D. T. Mainz, M. P. Repasky, E. H. Knoll, M. Shelley, J. K. Perry, D. E. Shaw, P. Francis, and P. S. Shenkin (2004). “Glide: A New Approach for Rapid, Accurate Docking and Scoring. 1. Method and Assessment of Docking Accuracy”. In: *Journal of Medicinal Chemistry* 47.7. doi: 10.1021/jm0306430, pp. 1739–1749. ISSN: 0022-2623. DOI: 10.1021/jm0306430. URL: <https://doi.org/10.1021/jm0306430>.
- Genheden, S. and U. Ryde (2015). “The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities”. In: *Expert Opinion on Drug Discovery* 10.5, pp. 449–461. ISSN: 1746-0441. DOI: 10.1517/17460441.2015.1032936.
- Goodsell, D. S., M. F. Sammer, A. J. Olson, and S. Forli (2021). “The AutoDock suite at 30”. In: *Protein Science* 30.1, pp. 31–43. ISSN: 0961-8368. DOI: <https://doi.org/10.1002/pro.3934>. URL: <https://onlinelibrary.wiley.com/doi/abs/10.1002/pro.3934>.
- Halgren, T. A., R. B. Murphy, R. A. Friesner, H. S. Beard, L. L. Frye, W. T. Pollard, and J. L. Banks (2004). “Glide: a new approach for rapid, accurate docking and scoring. 2. Enrichment factors in database screening”. In: *Journal of medicinal chemistry* 47.7, pp. 1750–1759. ISSN: 0022-2623. DOI: 10.1021/jm030644s.
- Humphrey, W., A. Dalke, and K. Schulten (1996). “VMD – Visual Molecular Dynamics”. In: *Journal of Molecular Graphics* 14, pp. 33–38.

- Irwin, J. J., K. G. Tang, J. Young, C. Dandarchuluun, B. R. Wong, M. Khurelbaatar, Y. S. Moroz, J. Mayfield, and R. A. Sayle (2020). “ZINC20-A Free Ultralarge-Scale Chemical Database for Ligand Discovery”. In: *Journal of chemical information and modeling* 60.12, pp. 6065–6073. DOI: 10.1021/acs.jcim.0c00675.
- Jakubec, D., P. Skoda, R. Krivak, M. Novotny, and D. Hoksza (2022). “PrankWeb 3: accelerated ligand-binding site predictions for experimental and modelled protein structures”. In: *Nucleic Acids Research* 50.W1, W593–W597. ISSN: 0305-1048. DOI: 10.1093/nar/gkac389. URL: <https://doi.org/10.1093/nar/gkac389>.
- Jendele, L., R. Krivak, P. Skoda, M. Novotny, and D. Hoksza (2019). “PrankWeb: a web server for ligand binding site prediction and visualization”. In: *Nucleic Acids Research* 47.W1, W345–W349. ISSN: 0305-1048. DOI: 10.1093/nar/gkz424. URL: <https://doi.org/10.1093/nar/gkz424>.
- Jia, Z., L. Yan, Z. Ren, L. Wu, J. Wang, J. Guo, L. Zheng, Z. Ming, L. Zhang, Z. Lou, and Z. Rao (May 2019). “Delicate structural coordination of the Severe Acute Respiratory Syndrome coronavirus Nsp13 upon ATP hydrolysis”. In: *Nucleic Acids Research* 47.12, pp. 6538–6550. ISSN: 0305-1048. DOI: 10.1093/nar/gkz409. eprint: <https://academic.oup.com/nar/article-pdf/47/12/6538/28917080/gkz409.pdf>. URL: <https://doi.org/10.1093/nar/gkz409>.
- Krivák, R. and D. Hoksza (2018). “P2Rank: machine learning based tool for rapid and accurate prediction of ligand binding sites from protein structure”. In: *Journal of Cheminformatics* 10.1, p. 39. ISSN: 1758-2946. DOI: 10.1186/s13321-018-0285-8. URL: <https://doi.org/10.1186/s13321-018-0285-8>.
- Laskowski, R. A. and M. B. Swindells (2011). “LigPlot+: Multiple Ligand–Protein Interaction Diagrams for Drug Discovery”. In: *Journal of Chemical Information and Modeling* 51.10, pp. 2778–2786. ISSN: 1549-9596. DOI: 10.1021/ci200227u.
- Le Guilloux, V., P. Schmidtke, and P. Tuffery (2009). “Fpocket: An open source platform for ligand pocket detection”. In: *BMC Bioinformatics* 10.1, p. 168. ISSN: 1471-2105. DOI: 10.1186/1471-2105-10-168. URL: <https://doi.org/10.1186/1471-2105-10-168>.
- Lemkul, J. A. (Oct. 2018). “From Proteins to Perturbed Hamiltonians: A Suite of Tutorials for the GROMACS-2018 Molecular Simulation Package [Article v1.0]”. In: *Living Journal of Computational Molecular Science* 1.1, p. 5068. DOI: 10.33011/livecoms.1.1.5068. URL: <https://livecomsjournal.org/index.php/livecoms/article/view/v1i1e5068>.
- Lu, C., C. Wu, D. Ghoreishi, W. Chen, L. Wang, W. Damm, G. A. Ross, M. K. Dahlgren, E. Russell, C. D. Von Bargen, R. Abel, R. A. Friesner, and E. D. Harder (2021). “OPLS4: Improving Force Field Accuracy on Challenging Regimes of Chemical Space”. In: *Journal of Chemical Theory and Computation* 17.7. doi: 10.1021/acs.jctc.1c00302, pp. 4291–4300. ISSN: 1549-9618. DOI: 10.1021/acs.jctc.1c00302. URL: <https://doi.org/10.1021/acs.jctc.1c00302>.
- Madhavi Sastry, G., M. Adzhigirey, T. Day, R. Annabhimoju, and W. Sherman (2013). “Protein and ligand preparation: parameters, protocols, and influence on virtual screening enrichments”. In: *Journal of Computer-Aided Molecular Design* 27.3, pp. 221–234. ISSN: 1573-4951. DOI: 10.1007/s10822-013-9644-8. URL: <https://doi.org/10.1007/s10822-013-9644-8>.
- Malone, B., N. Urakova, E. J. Snijder, and E. A. Campbell (2022). “Structures and functions of coronavirus replication–transcription complexes and their relevance for SARS-CoV-2 drug design”. In: *Nature Reviews Molecular Cell Biology* 23.1, pp. 21–39.
- Marecki, J. C., B. Belachew, J. Gao, and K. D. Raney (2021). “Chapter Ten - RNA helicases required for viral propagation in humans”. In: *Viral Replication Enzymes and their Inhibitors Part B*. Ed. by C. E. Cameron, J. J. Arnold, and L. S. Kaguni. Vol. 50. The Enzymes. Academic Press, pp. 335–367. DOI: <https://doi.org/10.1016/bs.enz.2021.09.005>. URL: <https://www.sciencedirect.com/science/article/pii/S1874604721000226>.

- Martinez, L. (2015). "Automatic Identification of Mobile and Rigid Substructures in Molecular Dynamics Simulations and Fractional Structural Fluctuation Analysis". In: *PLoS ONE* 10.3, e0119264. DOI: 10.1371/journal.pone.0119264.
- Miller, B. R. 3., T. D. J. McGee, J. M. Swails, N. Homeyer, H. Gohlke, and A. E. Roitberg (Sept. 2012). "MMPBSA.py: An Efficient Program for End-State Free Energy Calculations." eng. In: *Journal of chemical theory and computation* 8.9, pp. 3314–3321. ISSN: 1549-9618 (Print). DOI: 10.1021/ct300418h.
- Newman, J. A., A. Douangamath, S. Yadzani, Y. Yosaatmadja, A. Aimon, J. Brando-Neto, L. Dunnett, T. Gorrie-stone, R. Skyner, D. Fearon, M. Schapira, F. v. Delft, and O. Gileadi (2021). "Structure, mechanism and crystallographic fragment screening of the SARS-CoV-2 NSP13 helicase". In: *Nature Communications* 12.1, p. 4848. DOI: 10.1038/s41467-021-25166-6.
- O'Boyle, N. M., M. Banck, C. A. James, C. Morley, T. Vandermeersch, and G. R. Hutchison (2011). "Open Babel: An open chemical toolbox". In: *Journal of cheminformatics* 3.1, pp. 1–14.
- Pu, L., M. Naderi, T. Liu, H.-C. Wu, S. Mukhopadhyay, and M. Brylinski (2019). "e toxpred: A machine learning-based approach to estimate the toxicity of drug candidates". In: *BMC Pharmacology and Toxicology* 20, pp. 1–15.
- Pushpakom, S., F. Iorio, P. A. Eyers, K. J. Escott, S. Hopper, A. Wells, A. Doig, T. Williams, J. Latimer, C. McNamee, A. Norris, P. Sanseau, D. Cavalla, and M. Pirmohamed (2019). "Drug repurposing: progress, challenges and recommendations". In: *Nature Reviews Drug Discovery* 18.1, pp. 41–58. ISSN: 1474-1784. DOI: 10.1038/nrd.2018.168. URL: <https://doi.org/10.1038/nrd.2018.168>.
- Raubenolt, B. A., N. N. Islam, C. M. Summa, and S. W. Rick (2022). "Molecular dynamics simulations of the flexibility and inhibition of SARS-CoV-2 NSP 13 helicase". In: *Journal of Molecular Graphics and Modelling* 112, p. 108122. ISSN: 1093-3263. DOI: 10.1016/j.jmgm.2022.108122.
- Ravindranath, P. A., S. Forli, D. S. Goodsell, A. J. Olson, and M. F. Sanner (2015). "AutoDockFR: advances in protein-ligand docking with explicitly specified binding site flexibility". In: *PLoS computational biology* 11.12, e1004586.
- Robustelli, P., S. Piana, and D. E. Shaw (2018). "Developing a molecular dynamics force field for both folded and disordered protein states". In: *Proceedings of the National Academy of Sciences* 115.21, E4758–E4766. ISSN: 0027-8424. DOI: 10.1073/pnas.1800690115.
- Schrödinger Release 2022-3: Maestro. Schrödinger, LLC; New York, NY, USA: 2021. (2021).
- Schrödinger, LLC (Nov. 2015). "The PyMOL Molecular Graphics System, Version 1.8".
- Schrödinger, LLC (2023). "The PyMOL Molecular Graphics System, Verion 2.5.7". available online. URL: <https://pymol.org> (visited on 12/27/2024).
- Silva, A. W. S. d. and W. F. Vranken (2012). "ACPYPE - AnteChamber PYthon Parser interface". In: *BMC Research Notes* 5.1, p. 367. DOI: 10.1186/1756-0500-5-367.
- Śledź, P. and A. Caflisch (2018). "Protein structure-based drug design: from docking to molecular dynamics". In: *Current Opinion in Structural Biology* 48, pp. 93–102. ISSN: 0959-440X. DOI: <https://doi.org/10.1016/j.sbi.2017.10.010>. URL: <https://www.sciencedirect.com/science/article/pii/S0959440X17301100>.
- Spiegel, J. O. and J. D. Durrant (2020). "AutoGrow4: an open-source genetic algorithm for de novo drug design and lead optimization". In: *Journal of Cheminformatics* 12.1, p. 25. ISSN: 1758-2946. DOI: 10.1186/s13321-020-00429-4.
- Spratt, A. N., F. Gallazzi, T. P. Quinn, C. L. Lorson, A. Sönnnerborg, and K. Singh (2021). "Coronavirus helicases: Attractive and unique targets of antiviral drug-development and therapeutic patents". In: *Expert opinion on therapeutic patents* 31.4, pp. 339–350.
- Stank, A., D. B. Kokh, J. C. Fuller, and R. C. Wade (2016). "Protein Binding Pocket Dynamics". In: *Accounts of Chemical Research* 49.5. doi: 10.1021/acs.accounts.5b00516, pp. 809–815. ISSN:

REFERENCES

- 0001-4842. DOI: 10.1021/acs.accounts.5b00516. URL: <https://doi.org/10.1021/acs.accounts.5b00516>.
- Trott, O. and A. J. Olson (2010). “AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading”. In: *Journal of computational chemistry* 31.2, pp. 455–461. DOI: 10.1002/jcc.21334.
- Van Rossum, G. and F. L. Drake (2009). *Python 3 Reference Manual*. Scotts Valley, CA: CreateSpace. ISBN: 1441412697.